# Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab

> **NCT05602207** · PHASE4 · COMPLETED · sponsor: **Innovaderm Research Inc.** · enrollment: 24 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Abrocitinib

## Key facts

- **NCT ID:** NCT05602207
- **Lead sponsor:** Innovaderm Research Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-25
- **Primary completion:** 2024-12-03
- **Final completion:** 2025-01-09
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05602207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05602207, "Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05602207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*